< Back to main page

Immunity and inflammation


The MAP-SARS project aimed to provide a large population-based SARS-CoV-2 seroprevalence survey from Norway; we estimated SARS-CoV-2 seroprevalence before introduction of vaccines and described its distribution across demographic groups.

Specific objectives:

  • to conduct a comprehensive, population-based study to estimate the seroprevalence of SARS-CoV-2 antibodies in Norway's adult population before the commencement of vaccination programs. This involves understanding the extent of COVID-19 spread across different demographic groups, such as varying age groups and geographical regions, prior to vaccine availability. The study aims to achieve a detailed overview of the pandemic's impact in Norway during its early stages, utilizing a cross-sectional methodology where individuals are invited to provide both questionnaire responses and dried blood spot samples for analysis. Link to publication.
  • to comprehensively assess the prevalence of SARS-CoV-2 antibodies among the Norwegian population. By inviting over 100,000 adults to participate, the project seeks to understand the extent of past COVID-19 infections and the development of immunity. Participants contribute through a questionnaire and a blood spot sample, with individual antibody results provided back to them. This data, linked with national health registries, will explore correlations between COVID-19 spread and various health factors such as underlying diseases or medication use. The overarching goal is to enhance pandemic preparedness and response, both for the current situation and future scenarios, by generating valuable insights into the spread and immunity of COVID-19 within the population. Importantly, the project emphasizes voluntary participation and strict adherence to data protection and privacy regulations, ensuring the confidentiality of participant information. Link to project website.